Bank of New York Mellon’s Kiniksa Pharmaceuticals KNSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $14.9M | Buy |
232,531
+215,143
| +1,237% | +$11.2M | ﹤0.01% | 1813 |
|
|
2026
Q1 | $837K | Buy |
17,388
+2,917
| +20% | +$129K | ﹤0.01% | 3318 |
|
|
2025
Q4 | $597K | Sell |
14,471
-18,058
| -56% | -$724K | ﹤0.01% | 3507 |
|
|
2025
Q3 | $1.26M | Buy |
32,529
+790
| +2% | +$25.7K | ﹤0.01% | 3068 |
|
|
2025
Q2 | $878K | Sell |
31,739
-90,120
| -74% | -$2.29M | ﹤0.01% | 3202 |
|
|
2025
Q1 | $2.71M | Sell |
121,859
-192
| -0.2% | -$3.95K | ﹤0.01% | 2540 |
|
|
2024
Q4 | $2.41M | Buy |
122,051
+30,382
| +33% | +$693K | ﹤0.01% | 2676 |
|
|
2024
Q3 | $2.29M | Sell |
91,669
-23,474
| -20% | -$572K | ﹤0.01% | 2689 |
|
|
2024
Q2 | $2.15M | Buy |
115,143
+2,563
| +2% | +$48K | ﹤0.01% | 2757 |
|
|
2024
Q1 | $2.22M | Sell |
112,580
-20,973
| -16% | -$410K | ﹤0.01% | 2710 |
|
|
2023
Q4 | $2.34M | Sell |
133,553
-13,015
| -9% | -$214K | ﹤0.01% | 2745 |
|
|
2023
Q3 | $2.55M | Buy |
146,568
+17,790
| +14% | +$300K | ﹤0.01% | 2675 |
|
|
2023
Q2 | $1.81M | Buy |
128,778
+828
| +0.6% | +$11.1K | ﹤0.01% | 2898 |
|
|
2023
Q1 | $1.38M | Buy |
127,950
+603
| +0.5% | +$7.94K | ﹤0.01% | 2999 |
|
|
2022
Q4 | $1.91M | Buy |
127,347
+1,819
| +1% | +$26.5K | ﹤0.01% | 2878 |
|
|
2022
Q3 | $1.61M | Buy |
125,528
+4,891
| +4% | +$55.7K | ﹤0.01% | 2971 |
|
|
2022
Q2 | $1.17M | Sell |
120,637
-16,364
| -12% | -$153K | ﹤0.01% | 3135 |
|
|
2022
Q1 | $1.36M | Buy |
137,001
+3,095
| +2% | +$32.8K | ﹤0.01% | 3129 |
|
|
2021
Q4 | $1.58M | Sell |
133,906
-1,091
| -0.8% | -$13.4K | ﹤0.01% | 3134 |
|
|
2021
Q3 | $1.54M | Buy |
134,997
+3,638
| +3% | +$47.4K | ﹤0.01% | 3158 |
|
|
2021
Q2 | $1.83M | Sell |
131,359
-3,056
| -2% | -$46.4K | ﹤0.01% | 3040 |
|
|
2021
Q1 | $2.49M | Sell |
134,415
-2,448
| -2% | -$50.1K | ﹤0.01% | 2801 |
|
|
2020
Q4 | $2.42M | Buy |
136,863
+45,909
| +50% | +$806K | ﹤0.01% | 2733 |
|
|
2020
Q3 | $1.39M | Buy |
90,954
+13,437
| +17% | +$252K | ﹤0.01% | 2907 |
|
|
2020
Q2 | $1.98M | Buy |
77,517
+29,295
| +61% | +$612K | ﹤0.01% | 2689 |
|
|
2020
Q1 | $747K | Buy |
48,222
+1,998
| +4% | +$31.3K | ﹤0.01% | 3163 |
|
|
2019
Q4 | $512K | Sell |
46,224
-5,989
| -11% | -$52K | ﹤0.01% | 3584 |
|
|
2019
Q3 | $445K | Sell |
52,213
-4,158
| -7% | -$45.9K | ﹤0.01% | 3595 |
|
|
2019
Q2 | $764K | Buy |
56,371
+9,427
| +20% | +$146K | ﹤0.01% | 3375 |
|
|
2019
Q1 | $848K | Buy |
46,944
+26,374
| +128% | +$509K | ﹤0.01% | 3287 |
|
|
2018
Q4 | $578K | Buy |
20,570
+3,499
| +20% | +$73K | ﹤0.01% | 3411 |
|
|
2018
Q3 | $435K | Buy |
+17,071
| New | +$332K | ﹤0.01% | 3707 |
|
Other funds holding KNSA
RCMNY
BBA
TCM
SSC
Bank of New York Mellon's KNSA Position: Q2 2026 in Review
Bank of New York Mellon increased its Kiniksa Pharmaceuticals (KNSA) stake by 1,237% in Q2 2026, buying an estimated $11.2M and bringing the position to 232,531 shares worth $14.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1813.
Bank of New York Mellon first reported a position in KNSA in Q3 2018 and has held it in 32 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.
- Bank of New York Mellon held 232,531 shares of Kiniksa Pharmaceuticals worth $14.9M as of Q2 2026.
- Bank of New York Mellon bought 215,143 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $11.2M.
- Kiniksa Pharmaceuticals made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1813 holding.
- Bank of New York Mellon first reported a position in Kiniksa Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
- 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.